S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Fund/Baker Bros Advisors/Q2 2024

Baker Bros Advisors

Periodo: Q2 2024 · Depositato: 2024-08-14
Vedi su SEC EDGAR
AUM
$7.83B
Valore totale del portafoglio
Posizioni
95
Titoli dichiarati
Prima Posizione
INCY
23.8% $1.86B
Var. Trimestrali
+8 / -8
nuovi · usciti
⚠️Informativa sui Depositi 13F

I dati AUM mostrati sono calcolati sommando il valore di mercato dichiarato di tutte le posizioni nei depositi SEC 13F-HR — non rappresentano il patrimonio effettivo gestito dal fondo.

  • Escluse liquidità, obbligazioni, private equity, posizioni corte e azioni estere non soggette all'obbligo di dichiarazione.
  • Per le opzioni PUT e CALL, il Valore dichiarato è il valore nozionale delle azioni sottostanti — non il premio pagato. Ciò sovrastima significativamente il capitale effettivamente a rischio.
  • Il patrimonio reale del fondo è tipicamente superiore e include strategie, strumenti e posizioni che non compaiono mai in un 13F.
  • I depositi 13F riguardano i gestori istituzionali con ≥$100M in titoli 13F. Le posizioni riflettono le partecipazioni a fine trimestre, divulgate entro 45 giorni dalla fine del periodo.

Dati provenienti da SEC EDGAR. Questo tracker è a scopo puramente informativo e non costituisce consulenza finanziaria.

Partecipazioni in Portafoglio

Prime 30 posizioni

⚠️ Performance % calcolata dalla data di deposito ( 2024-08-14) si riferisce al titolo sottostante — non al P&L del derivato.
TickerEmittenteNozionalePortafoglio %Al DepositoOra (Fine Giornata)Dal DepositoAllocazione
INCYIncyte Corporation$1.86B23.81%$60.87$116.86+92.0%
23.8%
ONCBeiGene, Ltd.$1.51B19.27%$144.89$297.65+105.4%
19.3%
ACADACADIA Pharmaceuticals Inc.$696.8M8.90%$16.04$25.97+61.9%
8.9%
MDGLMadrigal Pharmaceuticals, Inc.$553.2M7.07%$279.31$528.10+89.1%
7.1%
RVMDRevolution Medicines, Inc.$293.8M3.75%$38.81$189.24+387.6%
3.8%
RYTMRhythm Pharmaceuticals, Inc.$262.7M3.36%$42.67$114.17+167.6%
3.4%
INSMInsmed Incorporated$239.6M3.06%$66.34$111.60+68.2%
3.1%
BCYCBicycle Therapeutics plc$190.3M2.43%$20.29$4.35-78.6%
2.4%
SMMTSummit Therapeutics Inc.$181.1M2.31%$8.14$15.42+89.4%
2.3%
KYMRKymera Therapeutics, Inc.$179.0M2.29%$30.95$113.51+266.8%
2.3%
EWTXEdgewise Therapeutics, Inc.$105.2M1.34%$19.38$39.56+104.1%
1.3%
ALKSAlkermes plc$100.8M1.29%$24.39$54.58+123.8%
1.3%
Insmed Incorporated$90.4M1.16%
1.2%
REPLReplimune Group, Inc.$90.4M1.16%$9.36$11.58+23.7%
1.2%
DNLIDenali Therapeutics Inc.$86.7M1.11%$22.01$25.83+17.4%
1.1%
ABCLAbCellera Biologics Inc.$81.5M1.04%$2.78$8.11+191.7%
1.0%
NRIXNurix Therapeutics, Inc.$81.0M1.04%$20.91$23.97+14.6%
1.0%
IMTXImmatics N.V.$74.9M0.96%$12.00$9.95-17.1%
1.0%
TRDAEntrada Therapeutics, Inc.$69.3M0.89%$14.32$7.72-46.1%
0.9%
RAREUltragenyx Pharmaceutical Inc.$60.3M0.77%$41.12$33.47-18.6%
0.8%
STOKStoke Therapeutics, Inc.$59.0M0.75%$13.87$32.70+135.8%
0.8%
Insmed Incorporated$56.2M0.72%
0.7%
KNSAKiniksa Pharmaceuticals International, plc$52.6M0.67%$18.00$64.53+258.5%
0.7%
IMCRImmunocore Holdings plc$51.4M0.66%$36.43$32.50-10.8%
0.7%
ARGXargenx SE$48.1M0.61%$434.22$939.68+116.4%
0.6%
KODKodiak Sciences Inc.$40.7M0.52%$2.37$38.54+1526.2%
0.5%
XENEXenon Pharmaceuticals Inc.$38.7M0.50%$37.69$60.96+61.7%
0.5%
PRLDPrelude Therapeutics Inc.$38.6M0.49%$3.77$4.91+30.2%
0.5%
IDYAIDEAYA Biosciences, Inc.$37.3M0.48%$35.92$37.65+4.8%
0.5%
CERSCerus Corporation$34.3M0.44%$1.72$3.16+83.7%
0.4%

Attività Trimestre su Trimestre

Q2 2024 vs. Q1 2024

Nuove Posizioni (8)

TickerEmittenteNozionaleDal Deposito
SMMTSummit Therapeutics Inc.$181.1M+89.4%
ALKSAlkermes plc$100.8M+123.8%
Insmed Incorporated$90.4M
Insmed Incorporated$56.2M
KNSAKiniksa Pharmaceuticals International, plc$52.6M+258.5%
ALMSAlumis Inc.$20.8M
MRUSMerus N.V.$17.8M
DBVTDBV Technologies S.A.$5.8M

Posizioni Chiuse (8)

TickerEmittenteNozionaleDal Deposito
KNSAKiniksa Pharmaceuticals, Ltd.$55.4M+258.5%
DBVTDBV Technologies S.A.$10.9M
HOOKHOOKIPA Pharma Inc.$5.8M
ALPNAlpine Immune Sciences, Inc.$3.2M
FDMT4D Molecular Therapeutics, Inc.$3.2M
MURAMural Oncology plc$1.1M
CABACabaletta Bio, Inc.$0.2M
CATXXXXXPerspective Therapeutics, Inc.$0.2M

Aumentate (8)

TickerEmittenteNozionaleVar. AzioniDal Deposito
INSMInsmed Incorporated$230.3M+942.6%+68.2%
KALAKALA BIO, Inc.$4.2M+234.3%
GBIOGeneration Bio Co.$1.9M+225.1%
TARAProtara Therapeutics, Inc.$0.3M+168.9%
DYNDyne Therapeutics, Inc.$15.6M+135.8%
BCYCBicycle Therapeutics plc$67.2M+90.2%-78.6%
FATEFate Therapeutics, Inc.$-3.5M+64.9%
NMRANeumora Therapeutics, Inc.$1.4M+63.2%

Ridotte (8)

TickerEmittenteNozionaleVar. AzioniDal Deposito
BCRXBioCryst Pharmaceuticals, Inc.$-51.0M-99.3%
ADAPYAdaptimmune Therapeutics plc$-14.8M-78.3%
AVTEAerovate Therapeutics, Inc.$-48.6M-62.6%
ROIVRoivant Sciences Ltd.$-48.6M-62.3%
AKROAkero Therapeutics, Inc.$-42.8M-59.6%
SAGESage Therapeutics, Inc.$-5.8M-58.0%
CERECerevel Therapeutics Holdings, Inc.$-39.7M-57.3%
ARGXargenx SE$-11.4M-26.0%+116.4%
Torna agli Hedge Fund